What Are the Biomarkers for Immunotherapy in SCLC?

Small-cell lung cancer (SCLC) is an aggressive malignancy that exhibits a rapid doubling time, a high growth fraction, and the early development of widespread metastases. The addition of immune checkpoint inhibitors to first-line chemotherapy represents the first significant improvement of systemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Longo, Vito, Catino, Annamaria, Montrone, Michele, Pizzutilo, Pamela, Annese, Tiziana, Pesola, Francesco, Marech, Ilaria, Cassiano, Sandro, Ribatti, Domenico, Galetta, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538776/
https://www.ncbi.nlm.nih.gov/pubmed/34681779
http://dx.doi.org/10.3390/ijms222011123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538776/
https://www.ncbi.nlm.nih.gov/pubmed/34681779
http://dx.doi.org/10.3390/ijms222011123

Ejemplares similares